Skip to Content

DEPO-MEDRONE WITH LIDOCAINE

Active substance: METHYLPREDNISOLONE ACETATE

View full screen / Print PDF » Download PDF ⇩
Transcript
FRONT PAGE

Depo-Medrone® with Lidocaine
(methylprednisolone acetate and lidocaine hydrochloride)

T03280

Patient Information Leaflet
Read all of this leaflet carefully before you start taking this medicine
• Keep this leaflet. You may need to read it again
• If you have any further questions please ask your doctor or pharmacist
• This medicine has been prescribed for you. Do not pass it to others. It may
harm them even if their symptoms are the same as yours
• If any of the side effects gets serious, or if you notice any side effects not
listed in this leaflet, tell your doctor or pharmacist
In this leaflet:
1. What Depo-Medrone with Lidocaine is and what it is used for
2. Before you are given Depo-Medrone with Lidocaine
3. How Depo-Medrone with Lidocaine is given to you
4. Possible side effects
5. How to Store Depo-Medrone with Lidocaine
6. Further information

1. WHAT DEPO-MEDRONE WITH LIDOCAINE IS AND WHAT IT IS USED FOR
Depo-Medrone with Lidocaine contains Methylprednisolone Acetate and Lidocaine.
Methylprednisolone belongs to a group of medicines called corticosteroids or steroids.
Corticosteroids are produced naturally in your body and are important for many body
functions. When injected into the body, such as in or near a joint, corticosteroids help
reduce symptoms caused by inflammatory or rheumatic conditions.
This medicine also contains Lidocaine which is a local anesthetic. Lidocaine helps to
reduce any local pain caused by injecting this medicine.
This medicine will be injected by a doctor or nurse to help treat the symptoms caused by
the following conditions:
• Bursitis: inflammation in the fluid containing spaces around the shoulder, knee and/or
elbow joints. For this condition this medicine will be injected directly into one or more of
these spaces.
• Osteoarthritis and rheumatoid arthritis: inflammation located in between the joints.
For these conditions this medicine will be injected directly into one or more joint spaces.
• Epicondylitis, tendonitis and tenosynovitis: Tennis elbow (epicondylitis),
inflammation in a tendon (tendonitis), or a tendon’s covering sheath (tenosynovitis). For
these conditions this medicine will be injected into the tendon or its tendon sheath.
Your doctor may use this medicine to treat conditions other than those listed above. Ask
your doctor if you are unsure why you have been given this medicine.

2. BEFORE YOU ARE GIVEN DEPO-MEDRONE WITH LIDOCAINE
Do not use Depo-Medrone with Lidocaine if:
• You think you have ever suffered an allergic reaction, or any other type of reaction after
being given:
Depo-Medrone with Lidocaine, any other medicine containing a corticosteroid or local
anaesthetic, any of the ingredients in this medicine (Section 6 of this leaflet contains a
list of ingredients). An allergic reaction may cause a skin rash or reddening, swollen face
or lips or shortness of breath.
• If you get a rash, or another symptom of an infection.
See your doctor immediately if you have any of the above.
Do not inject this medicine into:
• the Achilles tendon (which is located behind the ankle joint), or
• directly into a vein (intravenous), the spinal cord (intrathecal), into the nostrils
(intranasal) or in the eye (intraocular).
Take special care before taking Depo-Medrone with Lidocaine:
You must tell your doctor before you take this medicine if you have any of the following
conditions.
Your doctor may also have to monitor your treatment more closely, alter your dose or give
you another medicine.
• Chickenpox, shingles or a herpes eye infection. If you think you have been in contact
with someone with chickenpox or shingles and you have not already had these
illnesses, or if you are unsure if you have had them.
• Severe depression or manic depression (bipolar disorder). This includes having had
depression before while taking steroid medicines like Depo-Medrone with Lidocaine, or
having a family history of these illnesses.
• Diabetes (or if there is a family history of diabetes).
• Epilepsy.
• Glaucoma (increased pressure in the eye) or if there is a family history of glaucoma.
• You have recently suffered a heart attack.
• Heart problems, including heart failure or infections.
• Hypertension (high blood pressure).
• Hypothyroidism (an under-active thyroid).
• Joint infection – which is active and so requires treatment.
• Kidney or liver disease.
• Muscle problems (pain or weakness) have happened while taking steroid medicines in
the past.
• Myasthenia gravis (a condition causing tired and weak muscles).
• Osteoporosis (brittle bones).
• Skin abscess.
• Stomach ulcer or other serious stomach or intestinal problems.
• Thrombophlebitis - vein problems due to thrombosis (clots in the veins) resulting in
phlebitis (red, swollen and tender veins).
• Tuberculosis (TB) or if you have suffered tuberculosis in the past.

You must tell your doctor before you take this medicine if you have any of the conditions
listed above.
Taking other medicines
Always tell your doctor or pharmacist if you are taking any medicines (including any you
have bought without a prescription) as taking Depo-Medrone with Lidocaine with other
medicines could be harmful.
You should tell your doctor if you are taking any of the following medicines which can affect
the way Depo-Medrone with Lidocaine or the other medicine works:
• Acetazolamide - used to treat glaucoma and epilepsy.
• Aminoglutethimide – used for treating cancer.
• Anticoagulants - used to ‘thin’ the blood such as acenocoumarol, phenindione and
warfarin.
• Anticholinesterases - used to treat myasthenia gravis (a muscle condition) such as
distigmine and neostigmine.
• Antibiotics (such as erythromycin).
• Aspirin and non-steroidal anti-inflammatory medicines (also called NSAIDs) such as
ibuprofen used to treat mild to moderate pain.
• Barbiturates, carbamazepine, phenytoin and primidone – used to treat epilepsy.
• Carbenoxolone - used for heartburn and acid indigestion.
• Ciclosporin - used to treat conditions such as severe rheumatoid arthritis, severe
psoriasis or following an organ or bone marrow transplant.
• Digoxin - used for heart failure and/or an irregular heart beat.
• Diltiazem or mibefradil – used for heart problems or high blood pressure.
• Diuretics – sometimes called water tablets..
• Ketoconazole or itraconazole – used to treat fungal infections.
• Pancuronium – or other medicines called neuromuscular blocking agents which are
used in some surgical procedures.
• Rifampicin and rifabutin – antibiotics used to treat tuberculosis (TB).
• Vaccines - tell your doctor or nurse if you have recently had, or are about to have any
vaccination. You should not have ‘live’ vaccines while using this medicine. Other
vaccines may be less effective.
If you are taking long term medication(s)
If you are being treated for diabetes, high blood pressure or water retention (oedema) tell
your doctor as he/she may need to adjust the dose of the medicines used to treat these
conditions.
Before you have any operation tell your doctor, dentist or anesthetist that you are taking
this medicine.
If you require a test to be carried out by your doctor or in hospital it is important that
you tell the doctor or nurse that you are taking Depo-Medrone with Lidocaine. This
medicine can affect the results of some tests.
Pregnancy and breast feeding
You must tell your doctor if you are pregnant, think you might be pregnant or are trying to
become pregnant as this medicine could slow the baby’s growth.
Tell your doctor if you are breast feeding as small amounts of corticosteroid medicines may
get into breast milk.
If you continue breast-feeding while you are having treatment, your baby will need extra
checks to make sure he or she is not being affected by your medicine.
Driving and Using Machines
There are no special precautions while you are being treated with this medicine.
Important information about some of the ingredients of Depo-Medrone with
Lidocaine
This medicine contains benzyl alcohol. This medicine must not be given to premature
babies or neonates. It may cause toxic reactions and allergic reactions in infants and
children up to 3 years old.

3. HOW DEPO-MEDRONE WITH LIDOCAINE IS GIVEN TO YOU
Steroid Cards
Remember to always carry a Steroid Treatment Card. Make sure your doctor or
pharmacist has filled out the details of your medicine, including the dose and how
long you will require steroid treatment.
You should show your steroid card to anyone who gives you treatment (such as a doctor,
nurse or dentist) while you are taking this medicine, and for 3 months after your last
injection.
If you are admitted to hospital for any reason always tell your doctor or nurse that you are
taking this medicine. You can also wear a medic-alert bracelet or pendant to let medical
staff know that you are taking a steroid if you have an accident or become unconscious.
Dosage information
Your doctor will decide on the site of injection, how much of the medicine and how many
injections you will receive depending on the condition being treated and its severity. Your
doctor will inject you with the lowest dose for the shortest possible time to get effective
relief of your symptoms.
Adults
Your doctor/nurse will tell you how many injections you will require for the condition you are
being treated for, and when you will get them.
Joints - the normal dose for the injections into joint will depend on the size of the joint.
Large joints (e.g. knee, ankle and shoulder) may require 20 - 80 mg (0.5 – 2 ml), medium
sized joints (e.g. elbow or wrist) 10 - 40 mg (0.25 – 1 ml) and small joints (e.g. finger or toe
joints) may require a 4 - 10 mg (0.1 -0.25 ml) dose.
Joint injections may be given weekly over a period of several weeks, depending on how
quickly you respond to treatment.
Bursitis, epicondylitis (tennis elbow) and tendonitis – the usual dose is between 4-30 mg
(0.1 - 0.75 ml). In most cases repeat injections will not needed for bursitis and epicondylitis.
Repeat injections may be necessary to treat long standing tendonitis.

BACK PAGE

Elderly
Treatment will normally be the same as for younger adults. However your doctor may want
to see you more regularly to check how you are getting on with this medicine.
Children
Corticosteroids can affect growth in children so your doctor will prescribe the lowest dose
that will be effective for your child.

• Damage to the optic nerve or cataracts (indicated by failing eyesight).
• Thinning of the clear part at the front of the eye (cornea) or of the white part of the eye
(sclera).
• Worsening of viral or fungal eye infections.
• Protruding of the eyeballs (exophthalmos).
• Blurred or double vision.

Stopping/reducing the dose of your Depo-Medrone with Lidocaine
Your doctor will decide when it is time to stop your treatment.
You will need to come off this treatment slowly if you:
• have been given more than 6 mg (0.15 ml) Depo-Medrone with Lidocaine for more than
3 weeks;
• have been given high doses of Depo-Medrone with Lidocaine, over 32 mg (0.8 ml) daily,
even if it was only for 3 weeks or less;
• have already had a course of corticosteroid tablets or injections in the last year;
• already have problems with your adrenal glands (adrenocortical insufficiency) before
you started this treatment.

Hormones and metabolic system
• Slowing of normal growth in infants, children and adolescents which may be permanent.
• Irregular or no periods in women.
• Increased hair on the body and face in women (hirsutism).
• Round or moon-shaped face (Cushingoid facies).
• Increased appetite and weight gain.
• Diabetes or worsening of existing diabetes.
• Prolonged therapy can lead to lower levels of some hormones which in turn can cause
low blood pressure and dizziness. This effect may persist for months.
• The amount of certain chemicals (enzymes) called alanine transaminase, aspartate
transaminase and alkaline phosphatase that help the body digest drugs and other
substances in your body may be raised after treatment with a corticosteroid. The
change is usually small and the enzyme levels return to normal after your medicine has
cleared naturally from your system. You will not notice any symptoms if this happens,
but it will show up if you have a blood test.

You will need to come off this medicine slowly to avoid withdrawal symptoms. These
symptoms may include itchy skin, fever, muscle and joint pains, runny nose, sticky eyes,
sweating and weight loss.

Immune system
• Increased susceptibility to infections which can hide or change normal reactions to skin
tests, such as that for tuberculosis.

If your symptoms seem to return or get worse as your dose of this medicine is reduced tell
your doctor immediately.

Muscles, bones and joints
• Muscle weakness or wasting.
• Brittle bones (bones that break easily).
• Broken bones or fractures.
• Breakdown of bone due to poor circulation of blood, this causes pain in the hip.
• Torn muscle tendons causing pain and/or swelling.
• Muscle cramps or spasms.
• Swollen or painful joints due to infection.

If you are given more Depo-Medrone with Lidocaine than you should
If you think you have been given too many injections of this medicine please speak to your
doctor immediately.

Mental problems while taking Depo-Medrone with Lidocaine
Mental health problems can happen while taking steroids like Depo-Medrone with
Lidocaine (see also section 4, Possible Side Effects).
• These illnesses can be serious.
• Usually they start within a few days or weeks of starting the medicine.
• They are more likely to happen at high doses.
• Most of these problems go away if the dose is lowered or the medicine is stopped.
However if the problems do happen they might need treatment.
Talk to a doctor if you (or someone using this medicine) show any signs of mental
problems. This is particularly important if you are depressed, or might be thinking about
suicide. In a few cases mental problems have happened when doses are being lowered or
stopped.

4. POSSIBLE SIDE-EFFECTS
Like all steroids this medicine can cause side-effects, although not everybody gets them.
Your doctor will have given you this medicine for a condition which if not treated properly
could become serious.
In certain medical conditions medicines like Depo-Medrone and Lidocaine (steroids)
should not be stopped abruptly, if you suffer from any of the following symptoms
seek IMMEDIATE medical attention, your doctor will then decide whether you should
continue taking your medicine:
• Allergic reactions, such as skin rash, swelling of the face or wheezing and difficulty
breathing. This type of side effect is rare, but can be serious.
• Acute pancreatitis, stomach pain which may spread through to your back, possibly
accompanied by vomiting, shock and loss of consciousness.
• Burst or bleeding ulcers, symptoms of which are severe stomach pain which may go
through to the back and could be associated with bleeding from the back passage, black
or bloodstained stools and/or vomiting blood.
• Infections. This medicine can hide or change the signs and symptoms of some
infections, or reduce your resistance to the infection, so that they are hard to diagnose
at an early stage. Symptoms might include a raised temperature and feeling unwell.
Symptoms of a flare up of a previous TB infection could be coughing blood or pain in the
chest. This medicine may also make you more likely to develop a severe infection.
• Pulmonary embolus (blood clot in the lung) symptoms include sudden sharp chest
pain, breathlessness and coughing up blood.
• Raised pressure within the skull of children (pseudotumour cerebri) symptoms of
which are headaches with vomiting, lack of energy and drowsiness. This side-effect
usually occurs after treatment is stopped.
• Thrombophlebitis (blood clots or thrombosis in a leg vein), symptoms of which include
painful swollen, red and tender veins.
If you experience any of the following side effects, or notice any other unusual
effects not mentioned in this leaflet, tell your doctor immediately:
Blood, heart and circulation
• Problems with the pumping of your heart (heart failure) symptoms of which are swollen
ankles, difficulty in breathing and palpitations (awareness of heart beat) or irregular
beating of the heart, irregular or very fast or slow pulse.
• High blood pressure, symptoms of which are headaches, or generally feeling unwell.
• Increased numbers of white blood cells (leucocytosis).
Body water and salts
• Swelling and high blood pressure, caused by increased levels of water and salt content.
• Cramps and spasms, due to the loss of potassium from your body. In rare cases this can
lead to congestive heart failure (when the heart cannot pump properly).
Digestive system
• Nausea (feeling sick) or vomiting (being sick).
• Ulcers or thrush in the gullet (discomfort on swallowing).
• Indigestion.
• Bloated stomach.
• Persistent hiccups, especially when high doses are taken.
Eyes
• Glaucoma (raised pressure within the eye, causing pain in the eyes and headaches).
• Swollen optic nerve (causing a condition called papilloedema, and which may cause
sight disturbance).

Nerves and mood issues
Steroids including methylprednisolone can cause serious mental health problems.
These are common in both adults and children. They can affect about 5 in every 100
people taking medicines like methylprednisolone.
• Feeling depressed, including thinking about suicide.
• Feeling high (mania) or moods that go up and down.
• Feeling anxious, having problems sleeping, difficulty in thinking or being confused and
losing your memory.
• Feeling, seeing or hearing things which do not exist. Having strange and frightening
thoughts, changing how you act or having feelings of being alone.
• Other nervous system side effects may include breathing problems, convulsions,
dizziness, drowsiness, difficulty breathing, sensation of cold, heat or numbness, tinnitus
or unconsciousness.
Skin
• Abscess, especially near injection sites
• Acne.
• Poor wound healing.
• Thinning of skin with stretch marks.
• Bruising.
• Small purple/red patches on the skin.
• Pale or darker patches on your skin, or raised patches which are an unusual color.
If you experience any of the side effects listed above tell your doctor immediately.

5. HOW TO STORE DEPO-MEDRONE WITH LIDOCAINE
Do not store above 25°C. Protect from freezing.
This medicine must not be used after the expiry date ‘EXP’ shown on the container.
The doctor or pharmacist will keep this medicine in a safe place where children cannot
reach or see it.
If the medicine become discoloured or show any other signs of deterioration, you should
seek the advice of your doctor or pharmacist who will tell you what to do.
Medicines should not be disposed of via wastewater or household waste. Ask your
pharmacist how to dispose of medicines no longer required. These measures will help to
protect the environment.

6. FURTHER INFORMATION
What Depo-Medrone with Lidocaine contains
Each 1ml vial contains 40mg methylprednisolone acetate and 10mg lidocaine
hydrochloride.
This medicine also contains sodium chloride, myristyl-gamma-picolinium chloride, benzyl
alcohol, macrogol 3350, sodium hydroxide, hydrochloric acid and water for injection.
What a Depo-Medrone with Lidocaine looks like
Depo-Medrone with Lidocaine is a white, sterile suspension for injection contained in a
glass vial fitted with a turquoise coloured rubber cap.
Depo-Medrone with Lidocaine is available in packs of 1 vial, containing 1 ml of suspension.
Manufacturer and Product Licence Holder
This product is manufactured by Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870
Puurs, Belgium. It is procured from within the EU by the PL Holder: Swinghope Ltd,
Brandon House, Marlowe Way, Croydon CRO 4XS and repackaged by Interport Limited,
Brandon House, Marlowe Way, Croydon CRO 4XS.
POM

PL No: 10380/1517

Leaflet revision date: 10/04/12
Depo-Medrone® is a registered trademark of Pharmacia & Upjohn Limited, Great Britain.
T03280

FRONT PAGE

Depo-Medrone® with Lidocaine

(methylprednisolone acetate and lidocaine hydrochloride)

T03281

PHYSICIAN LEAFLET
Presentation
White, sterile aqueous suspension for injection containing 40 mg per ml methylprednisolone
acetate and 10 mg per ml lidocaine hydrochloride. Also contains macrogol 3350, sodium chloride,
myristyl-gamma-picolinium chloride, benzyl alcohol, sodium hydroxide, hydrochloric acid and
sterile water for injections.
Uses
Corticosteroid (glucocorticoid). Depo-Medrone with Lidocaine is indicated in conditions requiring a
glucocorticoid effect: e.g. anti-inflammatory or anti-rheumatic. It is recommended for local use
where the added anaesthetic effect would be considered advantageous.
Therapy with Depo-Medrone with Lidocaine does not obviate the need for the conventional
measures usually employed. Although this method of treatment will ameliorate symptoms, it is in
no sense a cure and the hormone has no effect on the cause of the inflammation.
Depo-Medrone with Lidocaine may be used as follows:
Intra-articular administration
Rheumatoid arthritis
Osteo-arthritis with an inflammatory component
Periarticular administration
Epicondylitis
Intrabursal administration
Subacromial bursitis
Prepatellar bursitis
Olecranon bursitis
Tendon sheath administration
Tendinitis
Tenosynovitis
Epicondylitis
Dosage and administration
Depo-Medrone with Lidocaine should not be mixed with any other preparation as flocculation of the
product may occur. Parenteral drug products should be inspected visually for particulate matter
and discoloration prior to administration whenever suspension and container permit.
Depo-Medrone with Lidocaine may be used by any of the following routes: intra-articular,
periarticular, intrabursal, and into the tendon sheath. It must not be used by the intrathecal or
intravenous routes. (See Contra-indications and Side-effects).
Undesirable effects may be minimized by using the lowest effective dose for the minimum period
(see Special warnings and precautions).
Depo-Medrone with Lidocaine vials are intended for single dose use only.
Intra-articular: Rheumatoid arthritis, osteo-arthritis. The dose of Depo-Medrone with Lidocaine
depends on the size of the joint and the severity of the condition. Repeated injections, if needed,
may be given at intervals of one to five or more weeks depending upon the degree of relief
obtained from the initial injection. A suggested dosage guide is: large joint (knee, ankle, shoulder),
0.5 - 2 ml (20 - 80 mg of steroid); medium joint (elbow, wrist), 0.25 - 1 ml (10 - 40 mg of steroid);
small joint (metacarpophalangeal, interphalangeal, sternoclavicular, acromioclavicular), 0.1 - 0.25
ml (4 - 10 mg of steroid).
Periarticular: Epicondylitis. Infiltrate 0.1 - 0.75 ml (4 - 30 mg of steroid) into the affected area.
Intrabursal: Subdeltoid bursitis, prepatellar bursitis, olecranon bursitis. For administration directly
into bursae, 0.1 - 0.75 ml (4 - 30 mg of steroid). In most acute cases, repeat injections are not
needed.
Into the tendon sheath: Tendinitis, tenosynovitis, epicondylitis. For administration directly into the
tendon sheath, 0.1 - 0.75 ml (4 - 30 mg of steroid). In recurrent or chronic conditions, repeat
injections may be necessary.
Special precautions should be observed when administering Depo-Medrone with Lidocaine:
Intra-articular injections should be made using precise, anatomical localisation into the synovial
space of the joint involved. The injection site for each joint is determined by that location where the
synovial cavity is most superficial and most free of large vessels and nerves. Suitable sites for
intra-articular injection are the knee, ankle, wrist, elbow, shoulder, phalangeal and hip joints. The
spinal joints, unstable joints and those devoid of synovial space are not suitable. Treatment failures
are most frequently the result of failure to enter the joint space. Intra-articular injections should be
made with care as follows: ensure correct positioning of the needle into the synovial space and
aspirate a few drops of joint fluid. The aspirating syringe should then be replaced by another
containing Depo-Medrone with Lidocaine. To ensure position of the needle synovial fluid should be
aspirated and the injection made.
After injection the joint is moved slightly to aid mixing of the synovial fluid and the suspension.
Subsequent to therapy care should be taken for the patient not to overuse the joint in which benefit
has been obtained. Negligence in this matter may permit an increase in joint deterioration that will
more than offset the beneficial effects of the steroid. Intrabursal injections should be made as
follows: the area around the injection site is prepared in a sterile way and a wheal at the site made
with 1 percent procaine hydrochloride solution. A 20 to 24 gauge needle attached to a dry syringe
is inserted into the bursa and the fluid aspirated. The needle is left in place and the aspirating
syringe changed for a small syringe containing the desired dose. After injection, the needle is
withdrawn and a small dressing applied. In the treatment of tenosynovitis and tendinitis, care
should be taken to inject Depo-Medrone with Lidocaine into the tendon sheath rather than into the
substance of the tendon. Due to the absence of a true tendon sheath, the Achilles tendon should
not be injected with Depo-Medrone with Lidocaine.
Children: For infants and children, the recommended dosage should be reduced, but dosage
should be governed by the severity of the condition rather than by strict adherence to the ratio
indicated by age or body weight.
Elderly patients: When used according to instructions, there is no information to suggest that a
change in dosage is warranted in the elderly. However, treatment of elderly patients, particularly if
long-term, should be planned bearing in mind the more serious consequences of the common
side-effects of corticosteroids in old age and close clinical supervision is required (see special
warnings and precautions).
Contra-indications, warnings, etc.
Contra-indications: Depo-Medrone with Lidocaine is contra-indicated where there is known
hypersensitivity to components or to any local anaesthetics of the amide type and in systemic
infection unless anti-infective therapy is employed.
Due to its potential for neurotoxicity, Depo-Medrone with Lidocaine must not be given by the
intrathecal route. In addition, as the product is a suspension it must not be given by the intravenous
route (see Side-effects).

Interactions
1. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.
Since concurrent administration of these agents results in a mutual inhibition of metabolism, it is
possible that convulsions and other adverse effects associated with the individual use of either
drug may be more apt to occur.
2. Drugs that induce hepatic enzymes, such as rifampicin, rifabutin, carbamazepine,
phenobarbitone, phenytoin, primidone, and aminoglutethimide enhance the metabolism of
corticosteroids and their therapeutic effects may be reduced.
3. Drugs such as erythromycin and ketoconazole may inhibit the metabolism of corticosteroids and
thus decrease their clearance.
4. Steroids may reduce the effects of anticholinesterases in myasthenia gravis. The desired effects
of hypoglycaemic agents (including insulin), anti-hypertensives and diuretics are antagonized by
corticosteroids, and the hypokalaemic effects of acetazolamide, loop diuretics, thiazide diuretics
and carbenoxolone are enhanced.
5. The efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy
and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.
6. The renal clearance of salicylates is increased by corticosteroids and steroid withdrawal may
result in salicylate intoxication. Salicylates and non-steroidal anti-inflammatory agents should be
used cautiously in conjunction with corticosteroids in hypothrombinaemia.
7. Steroids have been reported to interact with neuromuscular blocking agents such as
pancuronium with partial reversal of the neuromuscular block.
Effects on ability to drive and to use machines: None stated.
Other undesirable effects (frequency and seriousness)
Side-effects: The incidence of predictable undesirable side-effects associated with the use of
corticosteroids, including hypothalamic-pituitary-adrenal suppression correlates with the relative
potency of the drug, dosage, timing of administration and duration of treatment (see Special
warnings and precautions).
Side-effects for the Depo-Medrone component may be observed including:
PARENTERAL CORTICOSTEROID THERAPY - Anaphylactic reaction or allergic reactions,
hypopigmentation or hyperpigmentation, subcutaneous and cutaneous atrophy, sterile abscess,
post injection flare (following intra-articular use), Charcot-like arthropathy.
GASTRO-INTESTINAL - Dyspepsia, peptic ulceration with perforation and haemorrhage,
abdominal distension, oesophageal ulceration, oesophageal candidiasis, acute pancreatitis,
perforation of bowel.
Increases in alanine transaminase (ALT, SGPT) aspartate transaminase (AST, SGOT) and alkaline
phosphatase have been observed following corticosteroid treatment. These changes are usually
small, not associated with any clinical syndrome and are reversible upon discontinuation.
ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE EFFECTS - Increased susceptibility and
severity of infections with suppression of clinical symptoms and signs, opportunistic infections,
may suppress reactions to skin tests, recurrence of dormant tuberculosis (see Special warnings
and precautions).
MUSCULOSKELETAL - Proximal myopathy, osteoporosis, vertebral and long bone fractures,
avascular osteonecrosis, tendon rupture, aseptic necrosis, muscle weakness.
FLUID AND ELECTROLYTE DISTURBANCE - Sodium and water retention, potassium loss,
hypertension, hypokalaemic alkalosis, congestive heart failure in susceptible patients.
DERMATOLOGICAL - Impaired healing, petechiae and ecchymosis, thin fragile skin, skin atrophy,
bruising, striae, telangiectasia, acne.
ENDOCRINE/METABOLIC - Suppression of the hypothalamo-pituitary-adrenal axis, growth
suppression in infancy, childhood and adolescence, menstrual irregularity and amenorrhoea.
Cushingoid facies, hirsutism, weight gain, impaired carbohydrate tolerance with increased
requirement for antidiabetic therapy, negative nitrogen and calcium balance. Increased appetite.
NEUROPSYCHIATRIC - A wide range of psychiatric reactions including affective disorders (such
as irritable, euphoric, depressed and labile mood psychological dependence and suicidal
thoughts), psychotic reactions (including mania, delusions, hallucinations and aggravation of
schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive
dysfunction including confusion and amnesia have been reported for all corticosteroids. .
Reactions are common and may occur in both adults and children. Psychological effects have
been reported on withdrawal of corticosteroids; the frequency is unknown. Increased intra-cranial
pressure with papilloedema in children (pseudotumour cerebri) has been reported, usually after
treatment withdrawal of methylprednisolone.
OPHTHALMIC - Increased intra-ocular pressure, glaucoma, papilloedema, cataracts with possible
damage to the optic nerve, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal
disease, exophthalmos.
GENERAL - Leucocytosis, hypersensitivity including anaphylaxis, thrombo-embolism, nausea,
vertigo.
WITHDRAWAL SYMPTOMS - Too rapid a reduction of corticosteroid dosage following prolonged
treatment can lead to acute adrenal insufficiency, hypotension and death. However, this is more
applicable to corticosteroids with an indication where continuous therapy is given (see Special
warnings and precautions).
A ’withdrawal syndrome’ may also occur including, fever, myalgia, arthralgia, rhinitis, conjunctivitis,
painful itchy skin nodules and loss of weight.
Side-effects for the Lidocaine component include:
CENTRAL NERVOUS SYSTEM - Light-headedness, nervousness, apprehension, euphoria,
confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensation of heat,
cold, numbness, twitching, tremors, convulsions, loss of consciousness, respiratory depression,
respiratory arrest.
CARDIOVASCULAR SYSTEM - Bradycardia, hypotension, cardiovascular collapse, cardiac
arrest.
ALLERGIC REACTIONS - Cutaneous lesions, urticaria, oedema, anaphylactic reactions.
CERTAIN SIDE-EFFECTS REPORTED WITH SOME NON RECOMMENDED ROUTES OF
ADMINISTRATION:
Intrathecal: Usual systemic corticoid adverse reactions, headache, meningismus, meningitis,
paraplegia, spinal fluid abnormalities, nausea, vomiting, sweating, arachnoiditis, convulsions.
Extradural: Wound dehiscence, loss of sphincter control.
Intranasal: Permanent/temporary blindness, allergic reactions, rhinitis.
Ophthalmic (Subconjunctival): Redness and itching, abscess, slough at injection site, residue at
injection site, increased intra-ocular pressure, decreased vision - blindness, infection.

BACK PAGE

Miscellaneous: Scalp, tonsillar fauces, sphenopalatine ganglion: blindness.
Special warnings and precautions
Warnings and Precautions:
1. A Patient Information Leaflet is provided in the pack by the manufacturer.
2. Undesirable effects may be minimized by using the lowest effective dose for the minimum
period. Frequent patient review is required to appropriately titrate the dose against disease activity
(see Dosage and administration).
3. Patients should carry ’Steroid Treatment’ cards which give clear guidance on the precautions to
be taken to minimize risk and which provide details of prescriber, drug, dosage and the duration of
treatment.
4. Depo-Medrone with Lidocaine vials are intended for single dose use only. Any multidose use of
the product may lead to contamination.
5. Depo-Medrone with Lidocaine is not recommended for epidural, intranasal, intra-ocular, or any
other unapproved route of administration. See Side-effects section for details of side-effects
reported from some non-recommended routes of administration.
6. Due to the absence of a true tendon sheath, the Achilles tendon should not be injected with
Depo-Medrone with Lidocaine.
7. While crystals of adrenal steroids in the dermis suppress inflammatory reactions, their presence
may cause disintegration of the cellular elements and physiochemical changes in the ground
substance of the connective tissue. The resultant infrequently occurring dermal and/or subdermal
changes may form depressions in the skin at the injection site and the possibility of
depigmentation. The degree to which this reaction occurs will vary with the amount of adrenal
steroid injected. Regeneration is usually complete within a few months or after all crystals of the
adrenal steroid have been absorbed. In order to minimize the incidence of dermal and subdermal
atrophy, care must be exercised not to exceed recommended doses in injections. Multiple small
injections into the area of the lesion should be made whenever possible. The technique of
intra-articular injection should include precautions against injection or leakage into the dermis.
8. Systemic absorption of methylprednisolone occurs following intra-articular injection of
Depo-Medrone with Lidocaine. Systemic as well as local effects can therefore be expected.
9. Intra-articular corticosteroids are associated with a substantially increased risk of inflammatory
response in the joint, particularly bacterial infection introduced with the injection. Charcot-like
arthropathies have been reported particularly after repeated injections. Appropriate examination of
any joint fluid present is necessary to exclude any bacterial infection, prior to injection.
10. Following a single dose of Depo-Medrone with Lidocaine, plasma cortisol levels are reduced
and there is evidence of hypothalamic-pituitary-adrenal axis (HPA) suppression. This suppression
lasts for a variable period of up to 4 weeks. The usual dynamic tests of HPA axis function can be
used to diagnose evidence of impaired activity (e.g. Synacthen test).
11. Adrenal cortical atrophy develops during prolonged therapy and may persist for months after
stopping treatment. In patients who have received more than physiological doses of systemic
corticosteroids (approximately 6 mg methylprednisolone) for greater than 3 weeks, withdrawal
should not be abrupt. How dose reduction should be carried out depends largely on whether the
disease is likely to relapse as the dose of systemic corticosteroids is reduced. Clinical assessment
of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on
withdrawal of systemic corticosteroids, but there is uncertainty about HPA suppression, the dose of
systemic corticosteroid may be reduced rapidly to physiological doses. Once a daily dose of 6 mg
methylprednisolone is reached, dose reduction should be slower to allow the HPA-axis to recover.
Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to 3 weeks is
appropriate if it considered that the disease is unlikely to relapse. Abrupt withdrawal of doses up
to 32 mg daily of methylprednisolone for 3 weeks is unlikely to lead to clinically relevant HPA-axis
suppression, in the majority of patients. In the following patient groups, gradual withdrawal of
systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less:
• Patients who have had repeated courses of systemic corticosteroids, particularly if taken for
greater than 3 weeks.
• When a short course has been prescribed within one year of cessation of long-term therapy
(months or years).
• Patients who may have reasons for adrenocortical insufficiency other than exogenous
corticosteroid therapy.
• Patients receiving doses of corticosteroid greater than 32 mg daily of methylprednisolone.
• Patients repeatedly taking doses in the evening.
12. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be
administered concurrently.
13. Because rare instances of anaphylactic reactions have occurred in patients receiving
parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to
administration, especially when the patient has a history of drug allergy.
14. Corticosteroids may mask some signs of infection, and new infections may appear during their
use. Suppression of the inflammatory response and immune function increases the susceptibility
to fungal, viral and bacterial infections and their severity. The clinical presentation may often be
atypical and may reach an advanced stage before being recognized.
15. Chickenpox is of serious concern since this normally minor illness may be fatal in
immunosuppressed patients. Patients (or parents of children) without a definite history of
chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster
and if exposed they should seek urgent medical attention. Passive immunization with
varicella/zoster immunoglobulin (VZIG) is needed by exposed non-immune patients who are
receiving systemic corticosteroids or who have used them within the previous 3 months; this
should be given within 10 days of exposure to chickenpox. If a diagnosis of chickenpox is
confirmed, the illness warrants specialist care and urgent treatment. Corticosteroids should not be
stopped and the dose may need to be increased.
16. Live vaccines should not be given to individuals with impaired immune responsiveness. The
antibody response to other vaccines may be diminished.
17. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close
observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid
therapy, these patients should receive chemoprophylaxis.
18. This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with
a fatal "Gasping Syndrome" in premature infants.
19. Care should be taken for patients receiving cardioactive drugs such as digoxin because of
steroid induced electrolyte disturbance/potassium loss (see Side-effects).
20. The following precautions apply for parenteral corticosteroids: Following intra-articular
injection, a marked increase in pain accompanied by local swelling, further restriction of joint
motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and the
diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted.
No additional benefit derives from the intramuscular administration of Depo-Medrone
with Lidocaine. Where parenteral corticosteroid therapy for sustained systemic effect is desired,
plain Depo-Medrone should be used.
Local injection of a steroid into a previously infected joint is to be avoided.
Corticosteroids should not be injected into unstable joints.
Sterile technique is necessary to prevent infections or contamination.
Special precautions:
Particular care is required when considering the use of systemic corticosteroids in patients with the
following conditions and frequent patient monitoring is necessary.

1. Osteoporosis (post-menopausal females are particularly at risk).
2. Hypertension or congestive heart failure.
3. Existing or previous history of severe affective disorders (especially previous steroid psychosis).
4. Diabetes mellitus (or a family history of diabetes).
5. History of tuberculosis.
6. Glaucoma (or a family history of glaucoma).
7. Previous corticosteroid-induced myopathy.
8. Liver failure or cirrhosis.
9. Renal insufficiency.
10. Epilepsy.
11. Peptic ulceration.
12. Fresh intestinal anastomoses.
13. Predisposition to thrombophlebitis.
14. Abscess or other pyogenic infections.
15. Ulcerative colitis.
16. Diverticulitis.
17. Myasthenia gravis.
18. Ocular herpes simplex, for fear of corneal perforation.
19. Hypothyroidism.
20. Patients and/or carers should be warned that potentially severe psychiatric adverse reactions
may occur with systemic steroids (see section 4.8). Symptoms typically emerge within a few days
or weeks of starting treatment. Risks may be higher with high doses/systemic exposure (see also
section 4.5 Interaction with Other Medicaments and Other Forms of Interaction that can increase
the risk of side effects), although dose levels do not allow prediction of the onset, type, severity or
duration of reactions. Most reactions recover after either dose reduction or withdrawal, although
specific treatment may be necessary. Patients/carers should be encouraged to seek medical
advice if worrying psychological symptoms develop, especially if depressed mood or suicidal
ideation is suspected. Patients/carers should be alert to possible psychiatric disturbances that may
occur either during or immediately after dose tapering/withdrawal of systemic steroids, although
such reactions have been reported infrequently.
Particular care is required when considering the use of systemic corticosteroids in patients with
existing or previous history of severe affective disorders in themselves or in their first degree
relatives. These would include depressive or manic-depressive illness and previous steroid
psychosis.
Use in children: Corticosteroids cause growth retardation in infancy, childhood and adolescence
which may be irreversible. Treatment should be limited to the minimum dosage for the shortest
possible time.
Use in the elderly: The common adverse effects of systemic corticosteroids may be associated with
more serious consequences in old age, especially osteoporosis, hypertension, hypokalaemia,
diabetes, susceptibility to infection and thinning of the skin. Close clinical supervision is required to
avoid life-threatening reactions.
Use in Pregnancy and Lactation:
Pregnancy
The ability of corticosteroids to cross the placenta varies between individual drugs, however,
methylprednisolone does cross the placenta.
Administration of corticosteroids to pregnant animals can cause abnormalities of foetal
development including cleft palate, intra-uterine growth retardation and affects on brain growth and
development. There is no evidence that corticosteroids result in an increased incidence of
congenital abnormalities, such as cleft palate in man, however, when administered for long periods
or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth
retardation. Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to
corticosteroids but usually resolves spontaneously following birth and is rarely clinically important.
As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and
child outweigh the risks. When corticosteroids are essential, however, patients with normal
pregnancies may be treated as though they were in the non-gravid state.
The use of local anaesthetics such as lidocaine during labour and delivery may be associated with
adverse effects on mother and foetus. Lidocaine readily crosses the placenta.
Lactation
Corticosteroids are excreted in small amounts in breast milk, however, doses of up to 40mg daily
of methylprednisolone are unlikely to cause systemic effects in the infant. Infants of mothers taking
higher doses than this may have a degree of adrenal suppression, but the benefits of breastfeeding
are likely to outweigh any theoretical risk.
It is not known whether lidocaine is excreted in human breast milk.
Use in children: Corticosteroids cause growth retardation in infancy, childhood and adolescence
which may be irreversible. Treatment should be limited to the minimum dosage for the shortest
possible time.
Use in the elderly: The common adverse effects of systemic corticosteroids may be associated
with more serious consequences in old age, especially osteoporosis, hypertension, hypokalaemia,
diabetes, susceptibility to infection and thinning of the skin. Close clinical supervision is required to
avoid life-threatening reactions.
Overdosage: There is no clinical syndrome of acute overdosage with Depo-Medrone with
Lidocaine. Following overdosage the possibility of adrenal suppression should be guarded against
by gradual diminution of dose levels over a period of time. In such event the patient may require to
be supported during any further traumatic episode.
Incompatibilities (major): None stated.
Pharmaceutical precautions
Do not store above 25° C. Protect from freezing.
Depo-Medrone with Lidocaine should not be mixed with any other fluid. Discard any remaining
suspension after use.
Legal category
POM
Packaging quantities
1 ml vial pack.
Manufacturer and Product Licence Holder
This product is manufactured by Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs,
Belgium. It is procured from within the EU by the Product Licence Holder Swinghope Ltd., Brandon
House, Marlowe Way, Croydon CR0 4XS and repackaged by Interport Ltd., Brandon House,
Marlowe Way, Croydon CR0 4XS.
PL No: 10380/1517
Leaflet revision date: 19/06/12.
Depo-Medrone® is a registered trademark of Pharmacia Limited, UK.
T03281

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

(web4)